NO963850L - Heterosykliske forbindelser, deres fremstilling og anvendelse - Google Patents

Heterosykliske forbindelser, deres fremstilling og anvendelse

Info

Publication number
NO963850L
NO963850L NO963850A NO963850A NO963850L NO 963850 L NO963850 L NO 963850L NO 963850 A NO963850 A NO 963850A NO 963850 A NO963850 A NO 963850A NO 963850 L NO963850 L NO 963850L
Authority
NO
Norway
Prior art keywords
heterocyclic compounds
preparation
compounds
preparing
useful
Prior art date
Application number
NO963850A
Other languages
English (en)
Norwegian (no)
Other versions
NO963850D0 (no
Inventor
Palle Jakobsen
Anders Kanstrup
Peter Faarup
H Preben Olesen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO963850D0 publication Critical patent/NO963850D0/no
Publication of NO963850L publication Critical patent/NO963850L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO963850A 1994-03-14 1996-09-13 Heterosykliske forbindelser, deres fremstilling og anvendelse NO963850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK29594 1994-03-14
PCT/DK1995/000115 WO1995025110A1 (en) 1994-03-14 1995-03-10 Heterocyclic compounds, their preparation and use

Publications (2)

Publication Number Publication Date
NO963850D0 NO963850D0 (no) 1996-09-13
NO963850L true NO963850L (no) 1996-11-14

Family

ID=8091942

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963850A NO963850L (no) 1994-03-14 1996-09-13 Heterosykliske forbindelser, deres fremstilling og anvendelse

Country Status (18)

Country Link
US (1) US5536721A (de)
EP (1) EP0750621B1 (de)
JP (1) JPH09510223A (de)
KR (1) KR970701719A (de)
CN (1) CN1144529A (de)
AT (1) ATE182333T1 (de)
AU (1) AU697183B2 (de)
BR (1) BR9507073A (de)
CA (1) CA2185670A1 (de)
CZ (1) CZ265096A3 (de)
DE (1) DE69510928D1 (de)
HU (1) HUT76543A (de)
IL (1) IL112957A0 (de)
MX (1) MX9604023A (de)
NO (1) NO963850L (de)
PL (1) PL316239A1 (de)
WO (1) WO1995025110A1 (de)
ZA (1) ZA952086B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842176A1 (de) * 1995-07-31 1998-05-20 Novo Nordisk A/S Heterocyclische verbindungen, deren herstellung und verwendung.
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
AU3783497A (en) * 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
TR199901173T2 (xx) 1996-09-27 1999-07-21 Guilford Pharmaceuticals, Inc. Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
DE19801646A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
DE19801636A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
DE19801647A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte beta,gamma-annellierte Lactone
AU2241400A (en) 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス,エルエルシー 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
CN108218897B (zh) * 2018-03-02 2020-12-11 湘潭大学 多取代硒吩并吲哚及衍生物及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2185670A1 (en) 1995-09-21
JPH09510223A (ja) 1997-10-14
WO1995025110A1 (en) 1995-09-21
AU1945795A (en) 1995-10-03
HU9602522D0 (en) 1996-11-28
KR970701719A (ko) 1997-04-12
HUT76543A (en) 1997-09-29
CN1144529A (zh) 1997-03-05
BR9507073A (pt) 1997-09-09
IL112957A0 (en) 1995-06-29
MX9604023A (es) 1997-09-30
US5536721A (en) 1996-07-16
EP0750621A1 (de) 1997-01-02
PL316239A1 (en) 1997-01-06
NO963850D0 (no) 1996-09-13
ZA952086B (en) 1996-09-16
DE69510928D1 (de) 1999-08-26
EP0750621B1 (de) 1999-07-21
AU697183B2 (en) 1998-10-01
ATE182333T1 (de) 1999-08-15
CZ265096A3 (en) 1997-06-11

Similar Documents

Publication Publication Date Title
NO963850L (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
ATE265419T1 (de) Spiro(2.4)heptanaminocarbonsäure und ihre derivate
SE9503924D0 (sv) Novel opioid peptides
BR9910130A (pt) Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
ATE199013T1 (de) N-(4-substituerte benzyl)-2-aminolactamderivate
DK1039900T3 (da) Farmaceutisk præparat indeholdende sibutramin og orlistat
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
FI103116B1 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten, N-substituoitujen atsaheterosyklisten karboksyylihappojohdannaisten valmistamiseksi
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
MXPA02000242A (es) Analogos de 2-aminoindano.
ZA979647B (en) Heterocyclic compounds, compositions and uses.
NO970573L (no) Ylidenforbindelser og deres fremstilling
WO2001002340A3 (en) Novel aminoindanes
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
DK1025101T3 (da) Naphtho-imidazo[1,2-a]pyridinderivater, deres fremstilling og deres anvendelse ved behandlingen af sygdomme i centralnervesystemet
AU2287197A (en) Heterocyclic compounds and their preparation and use
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
DK0793665T3 (da) Heterocykliske forbindelser og deres fremstilling og anvendelse
NO993546L (no) 1,4-dihydropyridinderivater og deres anvendelse i terapi
TR200000916T2 (tr) İkameli piperidin türevleri.
SE9502877D0 (sv) Novel opioid peptides